News

The chief scientific officer of Aurion Biotech discussed the investigational cell therapy AURN001.

STZ eyetrial’s treatment rAAV8.hPDE6A was otherwise deemed well-tolerated.

The BLA submission comes after a series of delays which have pushed lovo-cel behind Vertex’s exa-cel in the race to approval.

The commercially available gene therapy, developed by Spark Therapeutics, was evaluated in multiple studies presented at ARVO’s 2023 conference.

The new positive data on the AAV based gene therapy builds upon real-world data presented at ARVO’s conference in 2022.

The research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.

JadiCell is already being evaluated for the treatment of COVID-19 associated ARDS in a phase 3 trial.

The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.

Review top news and interview highlights from the week ending April 21, 2023.

Overall, 6 patients were treated in a feasibility study for a disease control rate of 33.3%.

The research scientist at Moffitt Cancer Center shared the rationale behind the preclinical study she presented at the 2023 AACR annual meeting.

The pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.

The investigators created the largest known CAR-T atlas, with more than 800,000 cells in total, providing a new exploration into the phenotyping of T-cells.

Investigators have initiated the BASECAMP-1 trial of investigational agent A2B530 with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial.

The investigators from Children’s Hospital of Philadelphia discussed the follow-up studies they are conducting in light of their recent findings regarding DNA virus replication.

Vax-CAR-T cells significantly suppressed tumor growth in mouse models in both smaller and larger tumors.

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CAR-T therapy reduced disease progression risk by 74%, according to a data leak reported by STAT News. The data are expected to be presented on May 11 at the 2023 European Hematology Association Congress.

Recent data supported the TCR therapy’s pending BLA submission.

Among patients treated at the higher dose level in the investigator-initiated clinical trial, the objective response rate was 50%.

The course kicks off at 8 AM ET on Friday, April 28, 2023, and will feature talks on acute and chronic graft versus host disease, infection risk, vaccination, thrombotic microangiopathy, and maintenance strategies, among others.

The investigators from Children’s Hospital of Philadelphia discussed the potential implications of their research into human adenoviruses for the development of new gene delivery tools.

Next steps may include assessing AFM13 in combination with natural killer cells.

The assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.

Among 11 treated patients, 8 achieved a complete response.

Infection rates in patients receiving omidubicel post-stem cell transplant were about 20% less than those in the control group.

The data warrant further evaluation of ALLO-316 in patients with confirmed CD70+ tumors.

The professor for human genetics and neurology at the University of Miami Miller School of Medicine discussed the rapidly changing landscape of diagnosing and treating genetic disorders.

All treated eyes had stable or improved MLMT scores at 6 or 9 months of follow-up.